Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Serono and EPFL announce research partnership

Merck Serono and EPFL announce research partnership

1st November 2007

Merck Serono and Ecole Polytechnique Federale de Lausanne (EPFL) have signed a research collaboration agreement in the areas of neuroscience, oncology and drug delivery.

EPFL, one of two Swiss Federal Institutes of Technology, will see the introduction of three Merck Serono-endowed Chairs.

The Chair specialisms will include neurodegenerative diseases such as Alzheimer’s and Parkinson’s; oncology in partnership with the Swiss Institute of Experimental Cancer Research (ISREC) and innovative drug delivery with a focus on nanoparticle vaccines.

Elmar Schnee, president of Merck Serono, confirmed the company’s delight in forging a partnership with EPFL.

“Our collaboration will contribute to the advancement of basic research in areas of high unmet medical needs, such as neuroscience and oncology and to the improvement of drug delivery methods to more effectively treat patients with existing and new medicines.”

As part of the agreement, Mark Serono will donate CHF12.5 million (5 million pounds) for the Chairs.

The pharmaceutical company also confirmed that the professors heading the Chairs would be hired in a way that was consistent with the high standards of quality at EPFL.

Merck Serono is the division of Merck KGaA which specialises in innovative prescription pharmaceuticals.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.